Interpace Diagnostics (NASDAQ: IDXG) reported Q3 EPS of ($0.11), versus $0.00 reported last year. Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.57 million.

• Expanded Guidance of Revenues for the Year to a Range between $21 and $22 Million
• Revenue Grew to $5.8 Million in the Third Quarter 2018 or 37% over the Third Quarter 2017
• Year to Date Revenue of $16.1 Million Increased 39% over the Same Period of 2017
• Cash & Cash Equivalents of $8.0 Million; No Long-Term Debt
• Added $4.0 Million Line of Credit Availability
• Now Covered by 30 Regional Blue Cross/Blue Shield Plans for ThyGenX® and ThyraMIR®

Jack Stover, President and CEO of Interpace Diagnostics, said, “I am very pleased to report the third quarter of 2018 continues our track record of revenue growth with seven straight quarters of gains in both volume and reimbursement.” Mr. Stover continued, “Our thyroid and pancreatic franchises more than met our expectations. The expansion of our thyroid franchise with the launch of our new and expanded mutational panel, ThyGeNEXTTM, the addition of thyroid coverage by new 30 Blue Cross/Blue Shield plans including the BCBS Federal Employee Health Benefit Program with 5.3 million covered lives, as well as concurrent growth in evaluating thyroid slide biopsies, supported by the recent transition of former Rosetta Genomics customers, has provided us with the experience and confidence to expand our guidance for 2018 Revenues to range between $21 and $22 million.”

For earnings history and earnings-related data on Interpace Diagnostics (IDXG) click here.